LRCX 50/50 Scale-In Overweight: 1.75% Combined Target via $347.50 Tranche 1 / $322 Tranche 2 Limit with $295 Hard Stop
The Overweight rating captures the institutional directional view while the 50/50 scale-in architecture captures execution discipline by not paying full size at the most exposed price level. This structure implements the 9/30 binding lesson (mid-band sizing at +20%+ above 200 SMA with momentum confirming), the 9/29 binding lesson (scale into structural-support pullback zone rather than treating Hold as default), and acknowledges the 10/01 reflection binding (breakout-implied PT failed on volume confirmation — don't chase upper band). The Aggressive Analyst's thesis is correct but overreaches on full-size conviction; the Conservative Analyst is correct but overreaches on magnitude of trim. The Neutral Analyst's 1.75% combined with 50/50 scale-in is the calibrated middle ground that captures asymmetric upside ($475-500 on beat-and-raise) while capping downside through the $295 stop and collar hedge into the binary event. Base case PT $400 (prior consolidation zone); stretch $475-500 on confirmed beat-and-raise multiple expansion.
| Position | Action |
|---|---|
| +24% above 200 SMA with momentum confirming and no distribution signal | Mid-band sizing of 1.75% (mid-point of 1.5-2.0% Research Manager range) |
| At upper Bollinger Band tag into $350-360 overhead supply with 52% volume deficit | Scale-in structure over single-tranche deployment to avoid chasing |
| Beat-and-raise confirmed at Oct 22-29 earnings | Add 0.5-0.75% incremental weight on confirmation |
Lam Research's all-time record quarter ($6.72B revenue, 51.7% gross margins, 37.4% operating margins) represents a structural breakout driven by AI capex super-cycle positioning in HBM, advanced packaging, and GAA logic—not a cyclical top—and the stock remains undervalued at ~30x forward earnings despite world-class 65% ROE and accelerating capital return.
| Indicator | Value | Signal |
|---|---|---|
| Close | $347.49 | neutral |
| 10 EMA | $321.90 (+7.9% above) | bullish |
| 50 SMA | $305.78 (+13.6% above, turning up) | bullish |
| 200 SMA | $274.61 (+26.5% above) | bullish |
| MACD | +7.84 | bullish |
| MACD Signal Line | +1.40 | bullish |
| MACD Histogram | +6.44 (expanding) | bullish |
| RSI | 67.76 (from 36.03 on 2026-09-16) | bullish |
| Bollinger Upper Band | $350.48 | neutral |
| Bollinger Middle Band | $305.24 | bullish |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Pullback to 10 EMA / 50 SMA zone at $322 limit
Then: Execute 0.875% position at $322 limit
AI capex super-cycle provides sustained multi-year demand tailwind
↩ rebuts: “Bear claim that WFE cycle is mid-to-late stage”
EV: +25%+ (re-test of prior high at $438, potential break to new all-time highs above that) · concedes: China export controls are a legitimate recurring overhang and the most serious bear concern, though already priced in given collapsing Taiwan risk premium and Lam's status as one of only two global suppliers; High Beta of 1.86 is real and the stock will move with the tape in any downturn; Forward EPS of $11.74 implying 97% growth is likely 10-20% too optimistic; consensus should be pressure-tested; RSI at 67.76 approaching overbought territory and could see near-term consolidation
The risk-reward is inverted for LRCX: the stock is priced for cyclical perfection at a 30x forward P/E requiring 97% EPS growth, yet the company just experienced a 42% drawdown in 29 days, has highest NAND exposure in WFE group, and trades with 1.86 beta. Cycles always end, and the current setup—parabolic RSI, compressed ATR, overhead supply zone at $350-360, and receivables growing 2.2x faster than revenue—suggests the asymmetry favors the bears.
EV: roughly -5% to -8% · concedes: Net cash of $1.84B does provide some cushion in absolute drawdowns; Duopoly with AMAT does provide some pricing power (though also shared risk); RSI below 70 and MACD positive in the short term; AI capex cycle has some remaining momentum
→ vs conservative: The 'wait for $322 pullback' argument is a momentum killer; every day stock holds above $322, probability of that re-entry diminishes; if pullback comes, technical setup likely broken = falling knife not dip
→ vs conservative: Forward P/E 29.6x for 65% ROE, 25%+ revenue growth, net-cash is NOT expensive; comparing to historical P/E misses peer context where NVDA trades 35-40x, AVGO 35x, MU 30x+
→ vs conservative: July 42% crash is recency bias; fundamentals never stronger with Q3 FY26 record $6.72B revenue and 37.4% margins; NAND exposure now offset by HBM demand, GAA logic, advanced packaging
→ vs conservative: Beta 1.86 is addressed through 1.75% position sizing; waiting for 'lower beta' is code for underperforming the index
→ vs conservative: Waiting for confirmation often means paying 10-15% more; not risk management, opportunity cost in disguise
→ vs neutral: The 'wait for break above $352.56 resistance' asks you to pay $360 for same stock you can own at $347.50 today with defined $295 stop risk
→ vs neutral: KLAC and AMAT report mid-October set WFE tone; waiting for their prints means LRCX will have already moved; underowned, under-followed status = positive surprise potential
→ vs neutral: 5/10 neutral sentiment with zero bearish data points is green light, not yellow; at 8/10 bullish would be caution, at 5/10 with no negative chatter path of least resistance is up
| Bollinger Lower Band | $260.00 | bullish |
| ATR(14) | $13.82 (down from $16.38 peak on 2026-09-02) | bullish |
Support: 321.9 · 305.78 · 274.61 · 260 | Resistance: 350.48 · 352.56 · 360 · 370 · 400
LRCX technicals are unambiguously bullish across all trend and momentum indicators with price well above all moving averages in textbook stacked formation, MACD momentum regime confirmed positive since 2026-09-28, and RSI rising rapidly from oversold (36) toward overbought (68) without yet triggering cooling signals. Near-term resistance at the upper Bollinger Band ($350.48) and the prior breakdown zone ($350-360) warrants tactical caution, as does the unusually fast RSI recovery pace suggesting potential mean-reversion risk. ATR compression to $13.82 indicates healthy volatility normalization rather than a blow-off top, supporting the bullish thesis. For existing longs, trailing stops should be anchored to the 10 EMA at $321.90; new entries should await pullbacks to the $305-322 support zone or confirmed breaks above $352.56.
Market Cap
$434.86 billion
52-Week High
$438.50
52-Week Low
$131.02
50-Day MA
$305.50
200-Day MA
$274.15
Beta
1.859
Dividend Yield
0.39%
FY2026 Revenue
$23.23B
FY2026 Gross Profit
$11.73B
FY2026 Gross Margin
50.5%
FY2026 Operating Income
$8.20B
FY2026 Operating Margin
35.3%
FY2026 Net Income
$7.27B
FY2026 Diluted EPS
$5.76
FY2026 EBITDA
$8.86B
FY2026 Free Cash Flow
$4.89B
FY2025 Revenue
$18.44B
FY2024 Revenue
$14.91B
FY2023 Revenue
$17.43B
Q3 FY26 Revenue
$6.72B
Q3 FY26 Gross Margin
51.7%
Q3 FY26 Operating Margin
37.4%
Q3 FY26 Net Income
$2.28B (from $2,277M)
Q3 FY26 Diluted EPS
$1.81
Q3 FY26 FCF
$1.27B (from $1,268M)
Q2 FY26 Revenue
$5.84B (from $5,841M)
Total Assets
$23.53B
Cash & Equivalents
$5.58B
Total Debt
$3.73B
Net Cash Position
+$1.84B
Stockholders' Equity
$12.47B
Working Capital
$9.67B
Current Ratio
2.63x
Tangible Book Value
$10.58B
Debt/Equity
33.0%
Inventory
$4.28B
Receivables
$5.34B
FY2026 Operating Cash Flow
$5.86B
FY2026 CapEx
$966M
FY2026 FCF Margin
21.1%
FY2026 Dividends Paid
$1.27B
FY2026 Buybacks
$3.85B
FY2026 Total Capital Return
$5.12B
P/E (TTM)
58.4x
Forward P/E
29.6x
PEG Ratio
1.58
P/B
34.9x
EPS (TTM)
$5.95
Forward EPS
$11.74
ROE
65.1%
ROA
22.8%
Profit Margin (TTM)
31.3%
R&D (Q3 FY26)
$642.9M
SG&A (Q3 FY26)
$322.3M
Strengths
Concerns
Lam Research delivered record Q3 FY26 results with revenue of $6.72B and operating margin of 37.4%, while FY2026 full-year revenue grew 26% YoY to $23.23B with net income of $7.27B and diluted EPS of $5.76. The company maintains a fortress balance sheet with $1.84B net cash, $5.58B in cash, and a 2.63x current ratio, while returning $5.12B to shareholders through buybacks ($3.85B) and dividends ($1.27B), exceeding FCF of $4.89B. Valuation appears stretched on TTM P/E (58.4x) due to tax distortions, but forward P/E of 29.6x is more reasonable given the company's 65% ROE, expanding margins, and AI-driven semiconductor equipment tailwinds.
Macro: Soft landing consensus firmly priced (8% US recession odds); Fed hold regime with 96% odds of zero cuts in 2026; easing yields post-September jobs miss; Iran-war inflation spillover beyond oil supply chains; TSMC government-stake odds collapsed 27pp to 13%, reducing Taiwan geopolitical risk premium; global benign with UK/Japan recession odds at 8%/5%.